Lv3
330 积分 2023-07-09 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1小时前
待确认
Two Sides to the Story
1小时前
已完结
Immunotherapy for lung cancer
5个月前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
5个月前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
5个月前
已完结
Immunotherapy for lung cancer
5个月前
已完结
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib
7个月前
已完结
Cancer incidence and mortality in China, 2022
8个月前
已完结
The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations
8个月前
已完结
Staging Lung Cancer
9个月前
已完结
皖公网安备34019202002308
